Omega Therapeutics, Inc. (OMGA)

2.2650 -0.3150 (-12.21%) As of 03:34PM EDT. Market open.

Omega Therapeutics, Inc.

20 Acorn Park Drive
Cambridge, MA 02140
United States
617 949 4360
https://omegatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 93

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mahesh Karande	President, CEO & Board Director	910.39k	N/A	1974
Dr. Yan Moore M.D.	Chief Medical Officer	738.34k	N/A	1967
Mr. Anthony Mullin	Chief People Officer	N/A	N/A	N/A
Ms. Barbara Y. Chan	Senior Vice President of Finance	N/A	N/A	1964
Mr. Charles O'Donnell Ph.D.	VP and Head of Computational Genomics & Data Sciences	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Omega Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.